Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCom.int.bk.regs Regulatory News (CBKD)

Share Price Information for Com.int.bk.regs (CBKD)

Share Price is delayed by 15 minutes
Get Live Data
2.635    -0.015 (-0.57%)
Bid:
2.635
Ask:
2.64
Spread: 0.005 (0.19%)
Market Cap: $8.69b
CBKD Live PriceLast checked at - London Stock Exchange

Intraday Com.int.bk.regs Share Chart

  • This share is an international stock.

CIB 1Q23 Consolidated Financial Statements

15 May 2023 07:00

RNS Number : 3361Z
Commercial Intnl Bank (Egypt) SAE
14 May 2023
Β 

Commercial International Bank (Egypt) S.A.E.

Consolidated Financial Statements

Β 

March 31, 2023

Click on, or paste the following link into your web browser, to view the associated PDF document.http://www.rns-pdf.londonstockexchange.com/rns/3361Z_1-2023-5-14.pdf

Β 

Β 

Β 

Condensed Consolidated Interim Statement of Financial Position as at March 31, 2023

Β 

Notes

Mar. 31, 2023

Β 

Dec. 31, 2022

Β 

EGP Thousands

Β 

EGP Thousands

Β 

Assets

Β 

Β 

Β 

Β 

Cash and balances at the central bank

8

52,462,528

Β 

47,492,549

Β 

Due from banks

9

170,682,323

Β 

133,856,720

Β 

Loans and advances to banks, net

11

616,088

Β 

2,978,197

Β 

Loans and advances to customers, net

12

213,047,067

Β 

193,599,872

Β 

Derivative financial instruments

Β 

2,088,501

Β 

1,939,961

Β 

Investments

Β 

Β 

Β 

- Financial Assets at Fair Value through OCI

13

185,998,930

Β 

204,020,733

Β 

- Financial Assets at Amortized cost

13

43,654,330

Β 

34,524,760

Β 

- Investments in associates

14

157,091

Β 

186,062

Β 

Non current assets held for sale

29

220,335

Β 

-

Β 

Other assets

15

14,774,256

Β 

14,521,427

Β 

Goodwill

26

85,954

Β 

96,268

Β 

Intangible assets

27

21,597

Β 

24,188

Β 

Deferred tax assets

Β 

-

Β 

185,746

Β 

Property and equipment

16

2,478,113

Β 

2,405,434

Β 

Total assets

Β 

686,287,113

Β 

635,831,917

Β 

Liabilities and equity

Β 

Β 

Β 

Liabilities

Β 

Β 

Β 

Due to banks

17

8,286,885

Β 

3,496,698

Β 

Due to customers

18

576,828,746

Β 

531,616,550

Β 

Non current liabilities held for sale

30

890

Β 

-

Β 

Derivative financial instruments

Β 

8,294

Β 

219,752

Β 

Deferred tax liabilities

65,046

Β 

-

Β 

Current income tax liabilities

1,991,935

Β 

3,051,583

Β 

Other liabilities

19

16,078,448

Β 

11,606,912

Β 

Issued debt instruments

20

3,069,231

Β 

2,456,607

Β 

Other loans

Β 

9,586,379

Β 

7,978,975

Β 

Other provisions

21

8,700,532

Β 

7,066,672

Β 

Total liabilities

Β 

624,616,386

Β 

567,493,749

Β 

Equity

Β 

Β 

Β 

Β 

Issued and paid up capital

Β 

29,990,563

Β 

29,825,134

Β 

Reserves

Β 

23,559,843

Β 

19,643,327

Β 

Reserve for employee stock ownership plan (ESOP)

1,667,377

Β 

1,895,435

Β 

Retained earnings *

6,330,323

16,393,841

Total equity and net profit for the period / year

Β 

61,548,106

Β 

67,757,737

Β 

Non Controlling Interest

122,621

580,431

Β 

Total minority interest, equity and net profit for the period / year

61,670,727

68,338,168

Β 

Total liabilities and equity

Β 

686,287,113

Β 

635,831,917

Β 

Β 

Β 

Β 

The accompanying notes are an integral part of these financial statements .

Β 

Β 

(Limited review report attached)

* Including net profit for the current period

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Hussein Abaza

Hisham Ezz Al-Arab

Β 

CEO & Managing Director

Chairman

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Condensed Consolidated Interim Income Statement for the period ended March 31, 2023

Β 

Β 

Β 

Β 

Β 

Notes

Β 

Β 

Mar. 31, 2023

Β 

Mar. 31, 2022

Β 

Β 

EGP Thousands

Β 

EGP Thousands

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Interest and similar income

19,823,554

Β 

12,006,043

Β 

Interest and similar expense

(8,939,377)

Β 

(5,288,771)

Β 

Net interest income

Β 

10,884,177

Β 

6,717,272

Β 

Β 

Β 

Β 

Β 

Β 

Fee and commission income

2,005,304

Β 

1,203,252

Β 

Fee and commission expense

(792,175)

Β 

(515,125)

Β 

Net fee and commission income

Β 

1,213,129

Β 

688,127

Β 

Β 

Β 

Β 

Β 

Β 

Dividend income

Β 

32,362

Β 

37,800

Β 

Net trading income

5

Β 

1,851,908

Β 

732,821

Β 

Profits (Losses) on financial investments

13

Β 

70,920

Β 

1,040,297

Β 

Administrative expenses

Β 

(2,063,690)

Β 

(1,670,887)

Β 

Other operating (expenses) income

6

(2,040,922)

Β 

(1,431,967)

Β 

Goodwill amortization

26

Β 

(10,314)

Β 

(10,314)

Β 

Intangible assets amortization

27

Β 

(2,591)

Β 

(2,591)

Β 

Impairment release (charges) for credit losses

Β 

(944,829)

Β 

38,692

Β 

Bank's share in the profits / losses of associates

(14,871)

Β 

2,841

Β 

Profit before income tax

8,975,279

Β 

6,142,091

Β 

Β 

Β 

Β 

Β 

Income tax expense

28

(2,262,132)

Β 

(1,372,939)

Β 

Deferred tax assets (Liabilities)

28

(645,223)

Β 

(509,534)

Β 

Net profit from continued operations

Β 

6,067,924

Β 

4,259,618

Β 

Β 

Β 

Β 

Β 

Discontinued Operations

Β 

Β 

Β 

Net profit from discontinued operations

31

870

Β 

-

Β 

Net profit for the period

Β 

Β 

6,068,794

Β 

4,259,618

Β 

Β 

Β 

Β 

Β 

Β 

Non Controlling Interest

3,847

Β 

15,387

Β 

Β 

Bank's shareholders

6,064,947

Β 

4,244,231

Β 

Earning per share

7

Β 

Β 

Β 

Β 

Basic

1.81

Β 

1.26

Β 

Diluted

1.79

Β 

1.24

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Hussein Abaza

Β 

Hisham Ezz Al-Arab

CEO & Managing Director

Β 

Chairman

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Condensed Consolidated Interim statement of Comprehensive Income for the period ended March 31, 2023

Β 

Mar. 31, 2023

Β 

Mar. 31, 2022

Β 

EGP Thousands

Β 

EGP Thousands

Β 

Β 

Β 

Β 

Β 

Net profit for the period

Β 

6,068,794

Β 

4,259,618

Β 

Change in fair value of Financial investments measured at fair value through comprehensive income after tax

(8,522,293)

Β 

(3,961,167)

Β 

Transferred to RE from financial assets at fair value through comprehensive income

(1,895)

Β 

(4,201)

Β 

Cumulative foreign currencies translation differences

281,927

Β 

52,636

Β 

Effect of ECL in fair value of debt instruments measured at fair value through comprehensive income

208,752

Β 

101,602

Β 

Total comprehensive income for the period

(1,964,715)

Β 

448,488

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

As follows:

Β 

Bank's shareholders

(1,968,562)

433,101

Β 

Non Controlling Interest

3,847

15,387

Β 

Total comprehensive income for the period

(1,964,715)

448,488

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Condensed Consolidated Interim Cash flows for the period ended March 31 2023

Β 

Β 

Notes

Mar. 31, 2023

Β 

Mar. 31, 2022

EGP Thousands

Β 

EGP Thousands

Β 

Β 

Cash flow from operating activities

Β 

Β 

Profit before income tax from continued operations

8,975,279

Β 

6,142,091

Profit from discontinued operations

870

Β 

-

Adjustments to reconcile profits to net cash provided by operating activities

Β 

Β 

Β 

Fixed assets depreciation

16

228,065

Β 

223,781

Impairment (Released) charge for credit losses (Loans and advances to customers and banks)

Β 

707,740

Β 

(145,266)

Other provisions charges

21

464,311

Β 

1,036,252

Impairment (Released) charge for credit losses (due from banks)

Β 

2,096

Β 

4,776

Impairment (Released) charge for credit losses (financial investments)

234,993

Β 

101,798

Impairment (Released) charge for other assets

-

Β 

(277,768)

Exchange revaluation differences for financial assets at fair value through OCI and AC

(6,033,831)

Β 

63

Goodwill amortization

26

10,314

Β 

10,314

Intangible assets amortization

27

2,591

Β 

2,591

Utilization of other provisions

21

(345)

Β 

(156)

Other provisions no longer used

21

-

Β 

(385)

Exchange differences of other provisions

21

1,169,894

Β 

278,463

profits from selling property and equipment

Β 

(118)

Β 

(50)

profits from selling financial investments at fair value through OCI

13

(70,920)

Β 

(1,040,297)

Shares based payments

Β 

190,974

Β 

175,235

Bank's share in the profits / losses of associates

14,871

Β 

(2,841)

Operating profits before changes in operating assets and liabilities

5,896,784

Β 

6,508,601

Β 

Β 

Β 

Net decrease (increase) in assets and liabilities

Β 

Β 

Due from banks

Β 

12,110,117

Β 

25,468,271

Financial assets at fair value through P&L

Β 

-

Β 

239,339

Derivative financial instruments

Β 

(359,998)

Β 

(680,085)

Loans and advances to banks and customers

11 - 12

(17,792,410)

Β 

(12,821,977)

Other assets

Β 

(96,139)

Β 

1,844,416

Non current assets held for sale

(220,335)

Β 

-

Due to banks

17

4,790,187

Β 

2,859,939

Due to customers

18

45,212,196

Β 

21,780,515

Current income tax obligations paid

Β 

(270,197)

Β 

(259,516)

Non current liabilities held for sale

Β 

890

Β 

-

Other liabilities

Β 

(354,332)

Β 

1,860,904

Net cash generated from (used in) operating activities

Β 

48,916,763

Β 

46,800,407

Β 

Β 

Β 

Cash flow from investing activities

Β 

Β 

Payment for purchases of property, equipment and branches constructions

(457,850)

Β 

(92,999)

Proceeds from selling property and equipment

118

Β 

50

Proceeds from redemption of financial assets at amortized cost

Β 

196,783

Β 

2,609,283

Payment for purchases of financial assets at amortized cost

(8,533,818)

Β 

(2,474,553)

Payment for purchases of financial assets at fair value through OCI

(32,339,905)

Β 

(68,625,535)

Proceeds from selling financial assets at fair value through OCI

46,767,421

Β 

78,456,150

Payment for investment in subsidiaries.

(1,008,761)

Β 

-

Net cash generated from (used in) investing activities

4,623,988

Β 

9,872,396

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Condensed Consolidated Interim Cash flows for the period ended March 31, 2023 (Cont.)

Β 

Β 

Mar. 31, 2023

Β 

Mar. 31, 2022

EGP Thousands

Β 

EGP Thousands

Β 

Β 

Cash flow from financing activities

Β 

Β 

Other loans

Β 

1,607,404

Β 

1,035,994

Dividends paid

Β 

(1,988,585)

Β 

(4,410,322)

Issued debt instruments

612,624

Β 

253,338

Capital increase

165,429

Β 

122,716

Net cash generated from (used in) financing activities

396,872

Β 

(2,998,274)

Β 

Β 

Β 

Β 

Β 

Β 

Net (decrease) increase in cash and cash equivalent during the period

53,937,623

Β 

53,674,529

Beginning balance of cash and cash equivalent

92,969,526

Β 

61,065,822

Cash and cash equivalent at the end of the period

146,907,149

Β 

114,740,351

Β 

Β 

Β 

Β 

Cash and cash equivalent comprise:

Β 

Β 

Cash and balances at the central bank

Β 

52,462,528

Β 

30,581,505

Due from banks

Β 

170,733,811

Β 

121,128,084

Treasury bills and other governmental notes

10Β 

68,681,151

Β 

40,379,000

Obligatory reserve balance with CBE

Β 

(46,005,523)

Β 

(26,188,639)

Due from banks with maturities more than three months

(29,664,721)

Β 

(10,245,456)

Treasury bills with maturity more than three months

(69,300,097)

Β 

(40,914,143)

Total cash and cash equivalent

146,907,149

Β 

114,740,351

'

Β 

Β 

Β 

Β 

Β 

Β 

Condensed Consolidated Interim statement of changes in shareholders' equity for the period ended March 31, 2022

Β 

Mar. 31, 2022

Issued and paid up capital

Legal reserve

General reserve

General risk reserve

Reserve for transactions under common control

Capital reserve

Reserve for financial assets at fair value through OCI

Banking risks reserve

Retained earnings

Reserve for employee stock ownership plan

Cumulative foreign currencies translation differences

Total Shareholders Equity

Non Controlling Interest

Total

EGP Thousands

Beginning balance

19,702,418

3,293,074

28,260,532

1,550,906

8,183

16,000

641,372

9,141

13,696,402

1,674,392

(4,218)

68,848,202

454,535

69,302,737

Capital increase

122,716

-

502,922

-

-

-

-

-

-

(502,922)

-

122,716

-

122,716

Transferred to reserves

-

670,872

8,333,404

-

-

2,947

-

-

(9,007,223)

-

-

-

-

-

Dividends paid

-

-

-

-

-

-

-

-

(4,410,322)

-

-

(4,410,322)

-

(4,410,322)

Net profit of the period

-

-

-

-

-

-

-

-

4,244,231

-

-

4,244,231

15,387

4,259,618

Β 

Transferred to RE from financial assets at fair value through OCI

-

-

-

-

-

-

(4,201)

-

4,201

-

-

-

-

-

Net unrealized gain/(loss) on financial assets at fair value through OCI after tax

-

-

-

-

-

-

(3,961,167)

-

-

-

-

(3,961,167)

-

(3,961,167)

Transferred (from) to banking risk reserve

-

-

-

-

-

-

-

2,840

(2,840)

-

-

-

-

-

Effect of ECL in fair value of debt instruments measured at fair value through OCI

-

-

-

-

-

-

101,602

-

-

-

-

101,602

-

101,602

Cost of employees stock ownership plan (ESOP)

-

-

-

-

-

-

-

-

-

175,235

-

175,235

-

175,235

Cumulative foreign currencies translation differences

-

-

-

-

-

-

-

-

-

-

56,854

56,854

39,279

96,133

Balance at the end of the period

19,825,134

3,963,946

37,096,858

1,550,906

8,183

18,947

(3,222,394)

11,981

4,524,449

1,346,705

52,636

65,177,351

509,201

65,686,552

Β 

Β 

Β 

Β 

Condensed Consolidated Interim statement of changes in shareholders' equity for the period ended March 31, 2023

Β 

Β 

Β 

Β 

Mar. 31, 2023

Issued and paid up capital

Legal reserve

General reserve

General risk reserve

Reserve for transactions under common control

Capital reserve

Reserve for financial assets at fair value through OCI

Banking risks reserve

Retained earnings

Reserve for employee stock ownership plan

Cumulative foreign currencies translation differences

Total Shareholders Equity

Non Controlling Interest

Total

Β 

EGP Thousands

Beginning balance

29,825,134

3,963,946

27,096,858

1,550,906

8,183

18,947

(13,188,818)

11,981

16,393,841

1,895,435

181,324

67,757,737

580,431

68,338,168

Capital increase

165,429

-

-

-

-

-

-

-

-

-

-

165,429

-

165,429

Transferred to reserves

-

806,408

11,998,639

-

-

2,208

-

-

(12,388,223)

(419,032)

-

-

-

-

Dividends paid

-

-

-

-

-

-

-

-

(3,738,888)

-

-

(3,738,888)

(23,982)

(3,762,870)

Net profit of the period

-

-

-

-

-

-

-

-

6,064,947

-

-

6,064,947

3,847

6,068,794

Β 

Transferred to RE from financial assets at fair value through OCI

-

-

-

-

-

-

(1,895)

-

1,895

-

-

-

-

-

Change in non controlling interest from acquisition of subsidiaries

-

-

-

-

-

-

-

-

-

-

-

-

(536,867)

(536,867)

Reserve for transactions under common control

-

-

-

-

(679,155)

-

-

-

-

-

-

(679,155)

-

(679,155)

Net unrealised gain/(loss) on financial assets at fair value through OCI after tax

-

-

-

-

-

-

(8,522,293)

-

-

-

-

(8,522,293)

-

(8,522,293)

Transferred (from) to banking risk reserve

-

-

-

-

-

-

-

3,249

(3,249)

-

-

-

-

-

Effect of ECL in fair value of debt instruments measured at fair value through OCI

-

-

-

-

-

-

208,752

-

-

-

-

208,752

-

208,752

Β 

Cost of employees stock ownership plan (ESOP)

-

-

-

-

-

-

-

-

-

190,974

-

190,974

-

190,974

Cumulative foreign currencies translation differences

-

-

-

-

-

-

-

-

-

-

100,603

100,603

99,192

199,795

Β 

Balance at the end of the period

Β 

29,990,563

4,770,354

39,095,497

1,550,906

(670,972)

21,155

(21,504,254)

15,230

6,330,323

1,667,377

281,927

61,548,106

122,621

61,670,727

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
QRFNKQBKABKDBPD
Date   Source Headline
12th May 202610:18 amRNS1st Quarter Results
12th May 202610:16 amRNSCIB Consolidated Financial Statements 1Q26
12th May 202610:15 amRNS1Q26 Earnings Release
16th Mar 20267:00 amRNSResolutions Ordinary General Assembly March 2026
16th Mar 20267:00 amRNSResolutions Extraordinary GA March 2026
16th Mar 20267:00 amRNSResolutions Extraordinary GA March 2026
16th Mar 20267:00 amRNSResolutions Ordinary General Assembly March 2026
24th Feb 202612:31 pmRNSItems of Extraordinary GA
24th Feb 20267:00 amRNSPress Release dated 23th February 2026
19th Feb 20261:20 pmRNSItems of Extraordinary GA
19th Feb 20261:17 pmRNSInvitation to the Extraordinary GA 2026
19th Feb 20268:00 amRNSItems of OGA 2026
19th Feb 20268:00 amRNSInvitation to the OGA March 15
10th Feb 20267:00 amRNSCIB Summary of Board Resolution 9 Feb 2026
10th Feb 20267:00 amRNSFY25 Earnings Release
10th Feb 20267:00 amRNSCIB IFRS Consolidated Financial Statements FY25
15th Dec 20257:00 amRNSChange in Board of Directors
3rd Dec 20254:35 pmRNSCIB Bonus Shares Distribution 2025
4th Nov 20257:00 amRNSCIB Condensed Consolidated 3rd Quarter Results
4th Nov 20257:00 amRNSCIB 9M25 Earnings Release
4th Nov 20257:00 amRNS3rd Quarter Results
25th Sep 20253:55 pmRNSSummary of Resolutions - GAM September 2025
1st Sep 20257:02 amRNSInvitation to General Assembly September 2025
22nd Jul 20257:00 amRNSCIB 1H2025 Condensed Consolidated Financials
22nd Jul 20257:00 amRNSCIB 1H2025 Condensed Separate Financials
22nd Jul 20257:00 amRNS2Q25 Earnings Release
28th May 20256:00 pmRNSChanges to the Board of Directors
13th May 20257:00 amRNSSeparate- Q12025
13th May 20257:00 amRNS1Q25 Press Release
13th May 20257:00 amRNSConsolidated Financial Position at March 31.2025
24th Mar 20257:00 amRNSOrdinary General Assembly Resolutions Summary 2025
28th Feb 20257:00 amRNSGeneral Assembly 2025 - Discussion Items - amended
27th Feb 20257:47 amRNSInvitation to General Assembly 2025
27th Feb 20257:15 amRNSGeneral Assembly 2025 - Discussion Items
19th Feb 20257:00 amRNSCIB Annual Financial Report
19th Feb 20257:00 amRNSCIB FY2024 Earnings Release
6th Nov 20247:58 amRNSCIB gets regulatory approvals to changes to BoD
4th Nov 20247:00 amRNSEarnings Release 3Q.2024
4th Nov 20247:00 amRNSCIB-Separate Financial Statements 3Q.2024
4th Nov 20247:00 amRNSCIB-Consolidated Financial Statements 3Q.2024
1st Oct 20242:00 pmRNSCIB obtaining Long term loan from IFC
16th Sep 20248:00 amRNSChanges in CIB's Board of Directors
22nd Jul 20247:00 amRNSCIB H1-2024 Separate Financial Statements - E
22nd Jul 20247:00 amRNSH1.2024 Press Release
22nd Jul 20247:00 amRNSCIB H1-2024 Consolidated Financial Statements
13th May 20247:00 amRNS1st Quarter Results - Separate Statements
13th May 20247:00 amRNS1st Quarter Results - Consolidated Statements
26th Mar 20247:49 amRNSChanges in CIB's BOD - 25 March 2024
26th Mar 20247:00 amRNSOGM Resolutions - March 25th, 2024
26th Mar 20247:00 amRNSEGM Resolutions - March 25th, 2024

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.